Barney S Graham

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1490995/publications.pdf

Version: 2024-02-01

422 papers	68,944 citations	1238 110 h-index	1051 234 g-index
467 all docs	467 docs citations	467 times ranked	59035 citing authors

#	Article	IF	Citations
1	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine, 2021, 384, 403-416.	27.0	7,910
2	Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020, 367, 1260-1263.	12.6	7,517
3	An mRNA Vaccine against SARS-CoV-2 â€" Preliminary Report. New England Journal of Medicine, 2020, 383, 1920-1931.	27.0	2,719
4	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature, 2021, 593, 130-135.	27.8	1,904
5	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. New England Journal of Medicine, 2020, 383, 2427-2438.	27.0	1,242
6	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 2020, 586, 567-571.	27.8	1,153
7	Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7348-E7357.	7.1	944
8	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine, 2020, 383, 1544-1555.	27.0	936
9	Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus. Science, 2013, 342, 592-598.	12.6	797
10	Animal models for COVID-19. Nature, 2020, 586, 509-515.	27.8	705
11	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature, 2017, 543, 248-251.	27.8	699
12	Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine. Science, 2013, 341, 1359-1365.	12.6	686
13	Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. New England Journal of Medicine, 2021, 384, 80-82.	27.0	665
14	Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody. Science, 2013, 340, 1113-1117.	12.6	656
15	Pre-fusion structure of a human coronavirus spike protein. Nature, 2016, 531, 118-121.	27.8	623
16	Rapid COVID-19 vaccine development. Science, 2020, 368, 945-946.	12.6	623
17	Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. New England Journal of Medicine, 2021, 384, 2259-2261.	27.0	603
18	Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 16262-16267.	7.1	580

#	Article	IF	Citations
19	Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nature Medicine, 2015, 21, 1065-1070.	30.7	567
20	Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science, 2020, 369, 731-736.	12.6	534
21	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. New England Journal of Medicine, 2013, 369, 2083-2092.	27.0	518
22	Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell, 2020, 181, 1004-1015.e15.	28.9	506
23	Durability of mRNA-1273 vaccineâ€“induced antibodies against SARS-CoV-2 variants. Science, 2021, 373, 1372-1377.	12.6	459
24	Proof of principle for epitope-focused vaccine design. Nature, 2014, 507, 201-206.	27.8	451
25	Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses. Journal of Experimental Medicine, 2007, 204, 1405-1416.	8.5	428
26	Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. New England Journal of Medicine, 2021, 384, 1468-1470.	27.0	417
27	The histopathology of fatal untreated human respiratory syncytial virus infection. Modern Pathology, 2007, 20, 108-119.	5.5	414
28	Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Scientific Reports, 2018, 8, 15701.	3.3	408
29	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. New England Journal of Medicine, 2021, 385, 1774-1785.	27.0	402
30	Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis. Journal of Virology, 2008, 82, 2040-2055.	3.4	398
31	Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. New England Journal of Medicine, 2016, 375, 2037-2050.	27.0	391
32	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Science Translational Medicine, 2015, 7, 319ra206.	12.4	390
33	Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science, 2016, 351, 1339-1342.	12.6	370
34	Primary respiratory syncytial virus infection in mice. Journal of Medical Virology, 1988, 26, 153-162.	5.0	357
35	The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infectious Diseases, The, 2018, 18, e295-e311.	9.1	355
36	Rapid development of a DNA vaccine for Zika virus. Science, 2016, 354, 237-240.	12.6	348

#	Article	IF	Citations
37	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Science Translational Medicine, 2021, 13, .	12.4	347
38	A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases. Journal of Infectious Diseases, 2018, 218, 347-354.	4.0	333
39	Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes. Journal of Virology, 2011, 85, 7788-7796.	3.4	327
40	A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. New England Journal of Medicine, 2017, 376, 330-341.	27.0	314
41	Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nature Medicine, 2016, 22, 614-623.	30.7	313
42	Prefusion Fâ€“specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Science Translational Medicine, 2015, 7, 309ra162.	12.4	312
43	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. New England Journal of Medicine, 2016, 374, 1635-1646.	27.0	295
44	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Reports, 2022, 39, 110812.	6.4	287
45	Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIVâ€1 Candidate Vaccine Delivered by a Replicationâ€Defective Recombinant Adenovirus Vector. Journal of Infectious Diseases, 2006, 194, 1638-1649.	4.0	283
46	Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell, 2015, 162, 1090-1100.	28.9	278
47	Herpesvirus DNA Is Consistently Detected in Lungs of Patients with Idiopathic Pulmonary Fibrosis. Journal of Clinical Microbiology, 2003, 41, 2633-2640.	3.9	276
48	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell, 2016, 166, 609-623.	28.9	270
49	Evaluation of candidate vaccine approaches for MERS-CoV. Nature Communications, 2015, 6, 7712.	12.8	258
50	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo. Journal of Virology, 2014, 88, 12669-12682.	3.4	248
51	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science, 2021, 373, eabj0299.	12.6	244
52	Chimpanzee Adenovirus Vector Ebola Vaccine. New England Journal of Medicine, 2017, 376, 928-938.	27.0	243
53	Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet, The, 2018, 391, 552-562.	13.7	235
54	A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine, 2008, 26, 6338-6343.	3.8	230

#	Article	IF	Citations
55	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell, 2021, 184, 4203-4219.e32.	28.9	228
56	A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial. Vaccine Journal, 2006, 13, 1267-1277.	3.1	221
57	Flow Cytometry Reveals that H5N1 Vaccination Elicits Cross-Reactive Stem-Directed Antibodies from Multiple Ig Heavy-Chain Lineages. Journal of Virology, 2014, 88, 4047-4057.	3.4	220
58	High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. Cell, 2019, 179, 1636-1646.e15.	28.9	219
59	Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nature Immunology, 2019, 20, 362-372.	14.5	211
60	Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01. Journal of Virology, 2011, 85, 8954-8967.	3.4	209
61	A proof of concept for structure-based vaccine design targeting RSV in humans. Science, 2019, 365, 505-509.	12.6	207
62	Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet, The, 2014, 384, 2046-2052.	13.7	206
63	Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nature Reviews Microbiology, 2009, 7, 393-400.	28.6	203
64	Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2711-2716.	7.1	201
65	Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIVâ€1 DNA Candidate Vaccine. Journal of Infectious Diseases, 2006, 194, 1650-1660.	4.0	200
66	Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunological Reviews, 2011, 239, 149-166.	6.0	196
67	Respiratory Syncytial Virus: Virology, Reverse Genetics, and Pathogenesis of Disease. Current Topics in Microbiology and Immunology, 2013, 372, 3-38.	1.1	193
68	Next-generation influenza vaccines: opportunities and challenges. Nature Reviews Drug Discovery, 2020, 19, 239-252.	46.4	192
69	Diversion of HIV-1 vaccineâ€“induced immunity by gp41-microbiota cross-reactive antibodies. Science, 2015, 349, aab1253.	12.6	191
70	Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. Cell Reports, 2016, 16, 1485-1491.	6.4	190
71	Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2016, 16, 31-42.	9.1	187
72	Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Science Immunology, 2016, 1, .	11.9	180

#	Article	IF	Citations
73	Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature, 2021, 592, 623-628.	27.8	180
74	Priming with Secreted Glycoprotein G of Respiratory Syncytial Virus (RSV) Augments Interleukin-5 Production and Tissue Eosinophilia after RSV Challenge. Journal of Virology, 1998, 72, 2871-2880.	3.4	177
75	Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science, 2016, 351, 1343-1346.	12.6	176
76	A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial. Journal of Infectious Diseases, 2007, 196, 1732-1740.	4.0	175
77	DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infectious Diseases, The, 2011, 11, 916-924.	9.1	174
78	Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Medicine, 2018, 15, e1002493.	8.4	174
79	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science, 2021, 373, .	12.6	174
80	Opportunistic Infections in Endogenous Cushing's Syndrome. Annals of Internal Medicine, 1984, 101, 334.	3.9	172
81	The Role of IFN in Respiratory Syncytial Virus Pathogenesis. Journal of Immunology, 2002, 168, 2944-2952.	0.8	170
82	SARS-CoV-2 Viral Variantsâ€"Tackling a Moving Target. JAMA - Journal of the American Medical Association, 2021, 325, 1261.	7.4	165
83	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity, 2021, 54, 1636-1651.	14.3	165
84	Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nature Medicine, 2016, 22, 362-368.	30.7	163
85	Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. Journal of Virology, 2020, 94, .	3.4	162
86	Structure-Based Vaccine Antigen Design. Annual Review of Medicine, 2019, 70, 91-104.	12.2	160
87	Maturation of West Nile Virus Modulates Sensitivity to Antibody-Mediated Neutralization. PLoS Pathogens, 2008, 4, e1000060.	4.7	158
88	Fc Glycan-Mediated Regulation of Placental Antibody Transfer. Cell, 2019, 178, 202-215.e14.	28.9	157
89	Structural basis of respiratory syncytial virus neutralization by motavizumab. Nature Structural and Molecular Biology, 2010, 17, 248-250.	8.2	156
90	NK T Cells Contribute to Expansion of CD8 + T Cells and Amplification of Antiviral Immune Responses to Respiratory Syncytial Virus. Journal of Virology, 2002, 76, 4294-4303.	3.4	155

#	Article	IF	Citations
91	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. Journal of Virology, 2018, 92, .	3.4	155
92	Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. Journal of Virology, 2017, 91, .	3.4	148
93	Chimpanzee Adenovirus Vector Ebola Vaccine â€" Preliminary Report. New England Journal of Medicine, 2015, 373, 775-776.	27.0	147
94	Secreted Respiratory Syncytial Virus G Glycoprotein Induces Interleukin-5 (IL-5), IL-13, and Eosinophilia by an IL-4-Independent Mechanism. Journal of Virology, 1999, 73, 8485-8495.	3.4	143
95	Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. Cell, 2016, 167, 684-694.e9.	28.9	141
96	Transgenic Overexpression of Interleukin (IL)-10 in the Lung Causes Mucus Metaplasia, Tissue Inflammation, and Airway Remodeling via IL-13-dependent and -independent Pathways. Journal of Biological Chemistry, 2002, 277, 35466-35474.	3.4	139
97	Subunit Recombinant Vaccine Protects against Monkeypox. Journal of Immunology, 2006, 177, 2552-2564.	0.8	139
98	A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial. Journal of Infectious Diseases, 2011, 203, 1396-1404.	4.0	138
99	Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine, 2007, 25, 4085-4092.	3.8	134
100	Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infectious Diseases, The, 2016, 16, 311-320.	9.1	133
101	Vaccine development for respiratory syncytial virus. Current Opinion in Virology, 2017, 23, 107-112.	5.4	133
102	Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses. Journal of Clinical Immunology, 2021, 41, 906-913.	3.8	133
103	Herpes Simplex Virus Infection of the Adult Lower Respiratory Tract. Medicine (United States), 1983, 62, 384-394.	1.0	132
104	A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). PLoS ONE, 2011, 6, e21225.	2.5	131
105	QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans. Vaccine, 2001, 19, 2080-2091.	3.8	128
106	Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation. Immunity, 2018, 48, 339-349.e5.	14.3	126
107	Illness Severity, Viral Shedding, and Antibody Responses in Infants Hospitalized with Bronchiolitis Caused by Respiratory Syncytial Virus. Journal of Infectious Diseases, 2002, 185, 1011-1018.	4.0	125
108	Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses. PLoS ONE, 2010, 5, e9015.	2.5	125

#	Article	IF	Citations
109	A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. Nature Communications, 2017, 8, 676.	12.8	125
110	Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. ELife, 2020, 9, .	6.0	123
111	Regulatory T Cells Promote Early Influx of CD8⁺T Cells in the Lungs of Respiratory Syncytial Virus-Infected Mice and Diminish Immunodominance Disparities. Journal of Virology, 2009, 83, 3019-3028.	3.4	120
112	Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. Journal of Clinical Investigation, 2012, 122, 4606-4620.	8.2	120
113	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. Science, 2022, 376, eabn8897.	12.6	119
114	Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect. Journal of Infectious Diseases, 2013, 208, 418-422.	4.0	117
115	Antiviral Activity of Lovastatin against Respiratory Syncytial Virus In Vivo and In Vitro. Antimicrobial Agents and Chemotherapy, 2001, 45, 1231-1237.	3.2	114
116	History of passive antibody administration for prevention and treatment of infectious diseases. Current Opinion in HIV and AIDS, 2015, 10, 129-134.	3.8	114
117	Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology, 2000, 48, 237-247.	2.0	113
118	Selective Cyclooxygenase-1 and -2 Inhibitors Each Increase Allergic Inflammation and Airway Hyperresponsiveness in Mice. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1154-1160.	5.6	113
119	Zika Virus: Immunity and Vaccine Development. Cell, 2016, 167, 625-631.	28.9	113
120	Respiratory Syncytial Virus in Allergic Lung Inflammation Increases Muc5ac and Gob-5. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 306-312.	5.6	111
121	Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization. Journal of Virology, 2019, 93, .	3.4	111
122	Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination. Journal of Virology, 2010, 84, 4998-5006.	3.4	110
123	Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nature Structural and Molecular Biology, 2016, 23, 811-820.	8.2	110
124	Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic. Nature Immunology, 2018, 19, 20-28.	14.5	110
125	Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet, The, 2015, 385, 1545-1554.	13.7	109
126	Functional interrogation and mining of natively paired human VH:VL antibody repertoires. Nature Biotechnology, 2018, 36, 152-155.	17.5	109

#	Article	IF	Citations
127	Rhodococcus equiâ€"An Increasingly Recognized Opportunistic Pathogen:Report of 12 Cases and Review of 65 Cases in the Literature. American Journal of Clinical Pathology, 1995, 103, 649-655.	0.7	108
128	Respiratory syncytial virus infection prolongs methacholine-induced airway hyperresponsiveness in ovalbumin-sensitized mice. Journal of Medical Virology, 1999, 57, 186-192.	5.0	108
129	Respiratory syncytial virus infection in the absence of STAT1 results in airway dysfunction, airway mucus, and augmented IL-17 levels. Journal of Allergy and Clinical Immunology, 2005, 116, 550-557.	2.9	108
130	Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial. Journal of Infectious Diseases, 2015, 211, 549-557.	4.0	108
131	Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin. Immunity, 2019, 51, 398-410.e5.	14.3	107
132	Candidate AIDS Vaccines. New England Journal of Medicine, 1995, 333, 1331-1339.	27.0	106
133	Smallpox vaccines: Past, present, and future. Journal of Allergy and Clinical Immunology, 2006, 118, 1320-1326.	2.9	106
134	Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. PLoS Pathogens, 2015, 11, e1005035.	4.7	106
135	Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. Scientific Reports, 2016, 6, 34108.	3.3	106
136	Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F. Journal of Virology, 2010, 84, 12236-12244.	3.4	105
137	RhoA Signaling Is Required for Respiratory Syncytial Virus-Induced Syncytium Formation and Filamentous Virion Morphology. Journal of Virology, 2005, 79, 5326-5336.	3.4	104
138	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. PLoS Medicine, 2017, 14, e1002435.	8.4	104
139	Prolonged Production of TNF-Î± Exacerbates Illness during Respiratory Syncytial Virus Infection. Journal of Immunology, 2004, 173, 3408-3417.	0.8	103
140	Novel antigens for RSV vaccines. Current Opinion in Immunology, 2015, 35, 30-38.	5.5	102
141	Consensus summary report for CEPI/BC March 12â€"13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine, 2020, 38, 4783-4791.	3.8	102
142	Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 203-212.	2.1	101
143	A Phase 1/2 Study of a Multiclade HIVâ€1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIVâ€Uninfected East Africans (RV 172). Journal of Infectious Diseases, 2010, 201, 600-607.	4.0	100
144	Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus. Journal of Molecular Biology, 2011, 409, 853-866.	4.2	100

#	Article	IF	Citations
145	Structural Analysis of Respiratory Syncytial Virus Reveals the Position of M2-1 between the Matrix Protein and the Ribonucleoprotein Complex. Journal of Virology, 2014, 88, 7602-7617.	3.4	100
146	Immunological Lessons from Respiratory Syncytial Virus Vaccine Development. Immunity, 2019, 51, 429-442.	14.3	99
147	Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet, The, 2019, 393, 889-898.	13.7	99
148	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. Journal of Clinical Investigation, 2019, 129, 4838-4849.	8.2	95
149	Clinical Trials of HIV Vaccines. Annual Review of Medicine, 2002, 53, 207-221.	12.2	94
150	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Science Translational Medicine, 2022, 14, eabj7125.	12.4	93
151	Pathogenesis of Respiratory Syncytial Virus Vaccine-augmented Pathology. American Journal of Respiratory and Critical Care Medicine, 1995, 152, S63-S66.	5.6	92
152	A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. Scientific Reports, 2020, 10, 18149.	3.3	90
153	Pathogenesis of Respiratory Syncytial Virus Infection in the Murine Model. Proceedings of the American Thoracic Society, 2005, 2, 110-115.	3.5	89
154	Safety and Immunogenicity of a High-Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV-1â€“Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 254-261.	2.1	88
155	Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against DryvaxÂ® challenge in vaccinia-naÃ¯ve and vaccinia-immune individuals. Vaccine, 2007, 25, 1513-1525.	3.8	88
156	Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages. MBio, 2019, 10, .	4.1	88
157	T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochemical and Biophysical Research Communications, 2021, 538, 211-217.	2.1	88
158	A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nature Medicine, 2000, 6, 35-40.	30.7	87
159	Modified Vaccinia Ankara: Potential as an Alternative Smallpox Vaccine. Clinical Infectious Diseases, 2004, 38, 1749-1753.	5.8	86
160	High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology, 2009, 387, 414-426.	2.4	86
161	Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa. PLoS ONE, 2010, 5, e12873.	2.5	86
162	IL-13 Is Sufficient for Respiratory Syncytial Virus G Glycoprotein-Induced Eosinophilia After Respiratory Syncytial Virus Challenge. Journal of Immunology, 2003, 170, 2037-2045.	0.8	85

#	Article	IF	Citations
163	Preferential induction of cross-group influenza A hemagglutinin stemâ€“specific memory B cells after H7N9 immunization in humans. Science Immunology, 2017, 2, .	11.9	84
164	Advances in antiviral vaccine development. Immunological Reviews, 2013, 255, 230-242.	6.0	83
165	H5N1 Vaccineâ€“Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem. Journal of Immunology, 2015, 195, 602-610.	0.8	83
166	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccineâ€“boosted nonhuman primates. Science, 2021, 374, 1343-1353.	12.6	83
167	Safety and Immunogenicity of a Candidate HIV-1 Vaccine in Healthy Adults: Recombinant Glycoprotein (rgp) 120: A Randomized, Double-Blind Trial. Annals of Internal Medicine, 1996, 125, 270.	3.9	82
168	A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation. Nature Communications, 2016, 7, 13916.	12.8	81
169	Mycobacterium chelonae: A cause of nodular skin lesions with a proclivity for renal transplant recipients. American Journal of Medicine, 1989, 86, 173-177.	1.5	80
170	Safety and Immunogenicity of Env 2-3, a Human Immunodeficiency Virus Type 1 Candidate Vaccine, in Combination with a Novel Adjuvant, MTP-PE/MF59. AIDS Research and Human Retroviruses, 1996, 12, 683-693.	1.1	79
171	Respiratory syncytial virus infection does not increase allergen-induced type 2 cytokine production, yet increases airway hyperresponsiveness in mice. Journal of Medical Virology, 2001, 63, 178-188.	5.0	78
172	Quantitative and Qualitative Deficits in Neonatal Lung-Migratory Dendritic Cells Impact the Generation of the CD8+ T Cell Response. PLoS Pathogens, 2014, 10, e1003934.	4.7	78
173	Respiratory Syncytial Virus Immunobiology and Pathogenesis. Virology, 2002, 297, 1-7.	2.4	77
174	Respiratory Syncytial Virus (RSV) G Glycoprotein Is Not Necessary for Vaccine-Enhanced Disease Induced by Immunization with Formalin-Inactivated RSV. Journal of Virology, 2004, 78, 6024-6032.	3.4	77
175	Vaccines against respiratory syncytial virus: The time has finally come. Vaccine, 2016, 34, 3535-3541.	3.8	77
176	Role of Plasma Membrane Lipid Microdomains in Respiratory Syncytial Virus Filament Formation. Journal of Virology, 2003, 77, 1747-1756.	3.4	76
177	Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen. Journal of Infectious Diseases, 1998, 177, 301-309.	4.0	75
178	Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas. Viruses, 2019, 11, 212.	3.3	75
179	RhoA Interacts with the Fusion Glycoprotein of Respiratory Syncytial Virus and Facilitates Virus-Induced Syncytium Formation. Journal of Virology, 1999, 73, 7262-7270.	3.4	74
180	Novel Vaccine Technologies. JAMA - Journal of the American Medical Association, 2018, 319, 1431.	7.4	73

#	Article	IF	Citations
181	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e297-e306.	4.7	73
182	Respiratory Syncytial Virus Glycoprotein G Interacts with DC-SIGN and L-SIGN To Activate ERK1 and ERK2. Journal of Virology, 2012, 86, 1339-1347.	3.4	71
183	DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial. PLoS ONE, 2013, 8, e59340.	2.5	71
184	Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus. Immunity, 2019, 51, 735-749.e8.	14.3	71
185	The Morphology and Assembly of Respiratory Syncytial Virus Revealed by Cryo-Electron Tomography. Viruses, 2018, 10, 446.	3.3	69
186	Neonatal CD8 T-cell Hierarchy Is Distinct from Adults and Is Influenced by Intrinsic T cell Properties in Respiratory Syncytial Virus Infected Mice. PLoS Pathogens, 2011, 7, e1002377.	4.7	68
187	Effect of a Chikungunya Virusâ€“Like Particle Vaccine on Safety and Tolerability Outcomes. JAMA - Journal of the American Medical Association, 2020, 323, 1369.	7.4	68
188	Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV,the, 2019, 6, e667-e679.	4.7	67
189	Adjuvants influence the quantitative and qualitative immune response in BALBc mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine, 1997, 15, 525-532.	3.8	66
190	Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2021, 39, 3053-3066.	3.8	66
191	Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. ACS Infectious Diseases, 2018, 4, 788-796.	3.8	65
192	Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nature Medicine, 2022, 28, 383-391.	30.7	65
193	Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection. PLoS ONE, 2010, 5, e10555.	2.5	64
194	SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn. Annals of Internal Medicine, 2021, 174, 687-690.	3.9	64
195	Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Reports, 2021, 37, 109929.	6.4	64
196	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell, 2022, 185, 113-130.e15.	28.9	64
197	Reinfection of mice with respiratory syncytial virus. Journal of Medical Virology, 1991, 34, 7-13.	5.0	63
198	VÎ²14 + T Cells Mediate the Vaccine-Enhanced Disease Induced by Immunization with Respiratory Syncytial Virus (RSV) G Glycoprotein but Not with Formalin-Inactivated RSV. Journal of Virology, 2004, 78, 8753-8760.	3.4	63

#	Article	IF	Citations
199	Lymph Node Activation by PET/CT Following Vaccination With Licensed Vaccines for Human Papillomaviruses. Clinical Nuclear Medicine, 2017, 42, 329-334.	1.3	63
200	Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD. Cell Reports, 2019, 28, 3395-3405.e6.	6.4	63
201	Interleukin-4 Diminishes CD8⁺Respiratory Syncytial Virus-Specific Cytotoxic T-Lymphocyte Activity In Vivo. Journal of Virology, 1999, 73, 8944-8949.	3.4	63
202	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Vaccine, 2021, 39, 7394-7400.	3.8	63
203	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Statistical Communications in Infectious Diseases, 2017, 9, .	0.2	62
204	Alternative Mechanisms of Respiratory Syncytial Virus Clearance in Perforin Knockout Mice Lead to Enhanced Disease. Journal of Virology, 2001, 75, 9918-9924.	3.4	61
205	Primary Human mDC1, mDC2, and pDC Dendritic Cells Are Differentially Infected and Activated by Respiratory Syncytial Virus. PLoS ONE, 2011, 6, e16458.	2.5	61
206	Studies of High Doses of a Human Immunodeficiency Virus Type 1 Recombinant Glycoprotein 160 Candidate Vaccine in HIV Type 1-Seronegative Humans. AIDS Research and Human Retroviruses, 1994, 10, 1713-1723.	1.1	60
207	Serum vitamin A levels in respiratory syncytial virus infection. Journal of Pediatrics, 1994, 124, 433-436.	1.8	59
208	Safety and Immunogenicity of a Gag-Pol Candidate HIV-1 DNA Vaccine Administered by a Needle-Free Device in HIV-1-Seronegative Subjects. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 601-605.	2.1	59
209	Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. Journal of Infectious Diseases, 2017, 215, 1376-1385.	4.0	59
210	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Reports, 2020, 33, 108322.	6.4	59
211	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity, 2021, 54, 1869-1882.e6.	14.3	59
212	Immunological determinants of disease caused by respiratory syncytial virus. Trends in Microbiology, 1996, 4, 290-294.	7.7	58
213	IL-4 Diminishes Perforin-Mediated and Increases Fas Ligand-Mediated Cytotoxicity In Vivo. Journal of Immunology, 2000, 164, 3487-3493.	0.8	58
214	Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate. Journal of Virology, 2015, 89, 9499-9510.	3.4	58
215	Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nature Communications, 2017, 8, 14158.	12.8	58
216	RhoA Is Activated During Respiratory Syncytial Virus Infection. Virology, 2001, 283, 188-196.	2.4	57

#	Article	IF	Citations
217	Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity. PLoS ONE, 2010, 5, e11995.	2.5	57
218	Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization. Journal of Virology, 2010, 84, 630-638.	3.4	57
219	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nature Immunology, 2021, 22, 1306-1315.	14.5	57
220	Lessons from Failureâ€"Preparing for Future HIVâ€1 Vaccine Efficacy Trials. Journal of Infectious Diseases, 2005, 191, 647-649.	4.0	56
221	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Reports Medicine, 2021, 2, 100313.	6.5	56
222	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Science Translational Medicine, 2021, 13, .	12.4	56
223	Respiratory Syncytial Virus Infection Reinforces Reflex Apnea in Young Lambs. Pediatric Research, 1992, 31, 381-385.	2.3	55
224	Identification of an H-2Db-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus. Virology, 2005, 337, 335-343.	2.4	55
225	Immunoprophylaxis and Immunotherapy of Respiratory Syncytial Virusâ€"Infected Mice with Respiratory Syncytial Virusâ€"Specific Immune Serum. Pediatric Research, 1993, 34, 167-172.	2.3	54
226	HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable. Journal of Immunology, 2011, 187, 3391-3401.	0.8	54
227	Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nature Communications, 2017, 8, 1877.	12.8	53
228	Safety and Immunogenicity of a High-Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV-1â€"Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 254-261.	2.1	52
229	Therapeutic Vaccination Expands and Improves the Function of the HIV-Specific Memory T-Cell Repertoire. Journal of Infectious Diseases, 2013, 207, 1829-1840.	4.0	52
230	Protective Role of TNF-?? in Respiratory Syncytial Virus Infection In Vitro and In Vivo. American Journal of the Medical Sciences, 1996, 311, 201-204.	1.1	52
231	TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. Vaccine, 2009, 27, 3045-3052.	3.8	51
232	A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes. Journal of Infectious Diseases, 2016, 214, 1487-1491.	4.0	51
233	Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus. Human Vaccines and Immunotherapeutics, 2014, 10, 3446-3454.	3.3	50
234	Viruslike Particles Encapsidating Respiratory Syncytial Virus M and M2 Proteins Induce Robust T Cell Responses. ACS Biomaterials Science and Engineering, 2016, 2, 2324-2332.	5.2	50

#	Article	IF	Citations
235	Development of a potent Zika virus vaccine using self-amplifying messenger RNA. Science Advances, 2020, 6, eaba5068.	10.3	50
236	DNA Priming Prior to Inactivated Influenza A(H5N1) Vaccination Expands the Antibody Epitope Repertoire and Increases Affinity Maturation in a Boost-Intervalâ€“Dependent Manner in Adults. Journal of Infectious Diseases, 2013, 208, 413-417.	4.0	49
237	Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop. Vaccine, 2016, 34, 4843-4849.	3.8	49
238	The Zika virus envelope protein glycan loop regulates virion antigenicity. Virology, 2018, 515, 191-202.	2.4	49
239	Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. Science Translational Medicine, 2021, 13, .	12.4	49
240	Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. Current Topics in Microbiology and Immunology, 2013, 372, 391-404.	1.1	48
241	Chronic fibrosing mediastinitis and superior vena caval obstruction from blastomycosis. Annals of Thoracic Surgery, 1992, 54, 764-765.	1.3	47
242	Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054). PLoS ONE, 2010, 5, e13579.	2.5	47
243	Responses against a Subdominant CD8+ T Cell Epitope Protect against Immunopathology Caused by a Dominant Epitope. Journal of Immunology, 2010, 185, 4673-4680.	0.8	46
244	Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics. Vaccine, 2019, 37, 7394-7395.	3.8	46
245	Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Pediatric Infectious Disease Journal, 2004, 23, S46-S57.	2.0	44
246	Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. Bioconjugate Chemistry, 2016, 27, 2372-2385.	3.6	44
247	Signaling through the Prostaglandin I 2 Receptor IP Protects against Respiratory Syncytial Virus-Induced Illness. Journal of Virology, 2004, 78, 10303-10309.	3.4	43
248	Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7â€“9th Sep 2015. Vaccine, 2016, 34, 2865-2869.	3.8	43
249	Vaccination with Human Papillomavirus Pseudovirus-Encapsidated Plasmids Targeted to Skin Using Microneedles. PLoS ONE, 2015, 10, e0120797.	2.5	43
250	Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness. Journal of Infectious Diseases, 2019, 219, 59-67.	4.0	42
251	Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus. PLoS ONE, 2017, 12, e0186854.	2.5	42
252	The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nature Reviews Immunology, 2011, 11, 65-70.	22.7	41

#	Article	IF	Citations
253	A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies. Nature Communications, 2021, 12, 1722.	12.8	41
254	A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats. Journal of Virology, 2016, 90, 7508-7518.	3.4	40
255	Determinants of early life immune responses to RSV infection. Current Opinion in Virology, 2016, 16, 151-157.	5.4	40
256	Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization. Nature Microbiology, 2019, 4, 124-133.	13.3	40
257	Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial. PLoS ONE, 2011, 6, e24517.	2.5	39
258	HIV-1 Vaccine-Induced T-Cell Reponses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1. PLoS Pathogens, 2013, 9, e1003404.	4.7	39
259	Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice. Journal of Infectious Diseases, 2019, 220, 1577-1588.	4.0	39
260	Breakthrough Infections during Phase 1 and 2 Primeâ€Boost HIVâ€1 Vaccine Trials with Canarypox Vectors (ALVAC) and Booster Dose of Recombinant gp120 or gp160. Journal of Infectious Diseases, 2004, 190, 903-907.	4.0	38
261	A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. PLoS ONE, 2015, 10, e0128779.	2.5	38
262	Zika Virus Vaccine Development. Journal of Infectious Diseases, 2017, 216, S957-S963.	4.0	38
263	Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. Journal of Infectious Diseases, 2020, 222, 628-636.	4.0	38
264	Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respiratory Medicine,the, 2021, 9, 1111-1120.	10.7	38
265	Cyclooxygenase Inhibition Augments Allergic Inflammation through CD4-Dependent, STAT6-Independent Mechanisms. Journal of Immunology, 2005, 174, 525-532.	0.8	37
266	Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar. Journal of Immunology Research, 2019, 2019, 1-8.	2.2	37
267	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. Immunity, 2021, 54, 769-780.e6.	14.3	37
268	Endocarditis and Infections of Intravascular Devices Due to Eikenella corrodens. American Journal of the Medical Sciences, 1986, 292, 209-212.	1.1	36
269	Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development. Frontiers in Immunology, 2020, 11, 842.	4.8	36
270	Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses. Nature Communications, 2020, 11, 791.	12.8	36

#	Article	IF	Citations
271	A Filovirus-Unique Region of Ebola Virus Nucleoprotein Confers Aberrant Migration and Mediates Its Incorporation into Virions. Journal of Virology, 2008, 82, 6190-6199.	3.4	35
272	Genetic Vaccine for Respiratory Syncytial Virus Provides Protection Without Disease Potentiation. Molecular Therapy, 2014, 22, 196-205.	8.2	35
273	Antibody to the gp120 V1/V2 Loops and CD4+ and CD8+ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia. Journal of Immunology, 2014, 193, 6172-6183.	0.8	34
274	Is It Possible to Develop a â€œUniversalâ€•Influenza Virus Vaccine?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029413.	5.5	34
275	A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells. Journal of Immunology, 2019, 202, 1250-1264.	0.8	34
276	SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. Science Immunology, 2021, 6, .	11.9	34
277	Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nature Medicine, 2022, 28, 1022-1030.	30.7	34
278	Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. Journal of Clinical Immunology, 1992, 12, 429-439.	3.8	33
279	Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus. Journal of Infectious Diseases, 2016, 214, S497-S499.	4.0	33
280	Prototype pathogen approach for pandemic preparedness: world on fire. Journal of Clinical Investigation, 2020, 130, 3348-3349.	8.2	33
281	Whither monkeypox vaccination. Vaccine, 2011, 29, D60-D64.	3.8	32
282	HIV vaccine-induced sero-reactivity: A challenge for trial participants, researchers, and physicians. Vaccine, 2015, 33, 1243-1249.	3.8	32
283	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. Journal of Infectious Diseases, 2018, 217, 1280-1288.	4.0	32
284	Replication-Defective Adenovirus Vectors with Multiple Deletions Do Not Induce Measurable Vector-Specific T Cells in Human Trials. Journal of Virology, 2009, 83, 6318-6322.	3.4	31
285	Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector. Journal of Virology, 2016, 90, 10022-10038.	3.4	31
286	Memory Inflation Drives Tissue-Resident Memory CD8+ T Cell Maintenance in the Lung After Intranasal Vaccination With Murine Cytomegalovirus. Frontiers in Immunology, 2018, 9, 1861.	4.8	31
287	DNA vaccination before conception protects Zika virusâ€“exposed pregnant macaques against prolonged viremia and improves fetal outcomes. Science Translational Medicine, 2019, 11, .	12.4	31
288	Human Immunodeficiency Virus (HIV) Vaccine Trials: a Novel Assay for Differential Diagnosis of HIV Infections in the Face of Vaccine-Generated Antibodies. Journal of Virology, 2006, 80, 2092-2099.	3.4	30

#	Article	IF	Citations
289	Relative dominance of epitope-specific CD8+ T cell responses in an F1 hybrid mouse model of respiratory syncytial virus infection. Virology, 2007, 362, 314-319.	2.4	30
290	Targeting the Vaginal Mucosa with Human Papillomavirus Pseudovirion Vaccines Delivering Simian Immunodeficiency Virus DNA. Journal of Immunology, 2012, 188, 714-723.	0.8	30
291	Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate. Journal of Virology, 2017, 91, .	3.4	30
292	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Science Translational Medicine, 2020, 12, .	12.4	30
293	T Cell Receptor Clonotype Influences Epitope Hierarchy in the CD8+ T Cell Response to Respiratory Syncytial Virus Infection. Journal of Biological Chemistry, 2011, 286, 4829-4841.	3.4	29
294	HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission. PLoS Medicine, 2014, 11, e1001616.	8.4	29
295	Blastomycosis presenting as monarticular arthritis. The role of synovial fluid cytology. Arthritis and Rheumatism, 1985, 28, 516-521.	6.7	28
296	Treatment with Anti-LFA-1 Delays the CD8 + Cytotoxic-T-Lymphocyte Response and Viral Clearance in Mice with Primary Respiratory Syncytial Virus Infection. Journal of Virology, 2004, 78, 3014-3023.	3.4	28
297	Novel Approach for Differential Diagnosis of HIV Infections in the Face of Vaccine-Generated Antibodies. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 304-312.	2.1	28
298	Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. Journal of Infectious Diseases, 2016, 213, 541-550.	4.0	28
299	Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera. Scientific Reports, 2018, 8, 8628.	3.3	28
300	Immunological goals for respiratory syncytial virus vaccine development. Current Opinion in Immunology, 2019, 59, 57-64.	5.5	28
301	DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases. Hum Vaccin, 2009, 5, 623-626.	2.4	27
302	Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1â€“Exposed Newborn Infants. Journal of Infectious Diseases, 2021, 224, 1916-1924.	4.0	27
303	Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus. PLoS ONE, 2016, 11, e0159709.	2.5	27
304	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. PLoS ONE, 2017, 12, e0185959.	2.5	27
305	The Complex Relationship between Respiratory Syncytial Virus and Allergy in Lung Disease. Viral Immunology, 2003, 16, 25-34.	1.3	26
306	Epitope-Specific Serological Assays for RSV: Conformation Matters. Vaccines, 2019, 7, 23.	4.4	26

#	Article	IF	Citations
307	Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen. PLoS Biology, 2019, 17, e3000164.	5.6	26
308	Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B. Pathogens and Immunity, 2019, 4, 294.	3.1	26
309	Modified Vaccinia Virus Ankara Immunization Protects against Lethal Challenge with Recombinant Vaccinia Virus Expressing Murine Interleukin-4. Journal of Virology, 2004, 78, 12471-12479.	3.4	25
310	HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. Journal of Clinical Investigation, 2014, 124, 4843-4856.	8.2	25
311	IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouse. Microbes and Infection, 2006, 8, 2880-2889.	1.9	24
312	Epitope-Specific Regulatory CD4 T Cells Reduce Virus-Induced Illness while Preserving CD8 T-Cell Effector Function at the Site of Infection. Journal of Virology, 2010, 84, 10501-10509.	3.4	24
313	Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab. Journal of Virology, 2017, 91, .	3.4	24
314	An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial. Npj Vaccines, 2017, 2, 15.	6.0	24
315	DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial. PLoS ONE, 2018, 13, e0206837.	2.5	24
316	Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. Vaccines, 2021, 9, 73.	4.4	24
317	Determinants and kinetics of cytokine expression patterns in lungs of vaccinated mice challenged with respiratory syncytial virus. Vaccine, 1997, 15, 597-602.	3.8	23
318	Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. Vaccine, 2007, 25, 7737-7742.	3.8	23
319	Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. Journal of Leukocyte Biology, 2008, 84, 748-759.	3.3	23
320	Characterization of Respiratory Syncytial Virus M- and M2-Specific CD4 T Cells in a Murine Model. Journal of Virology, 2009, 83, 4934-4941.	3.4	23
321	Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects. Journal of Infectious Diseases, 2011, 204, 1541-1549.	4.0	23
322	Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011). PLoS ONE, 2014, 9, e91366.	2.5	23
323	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. PLoS ONE, 2015, 10, e0136626.	2.5	23
324	Next-Generation Influenza Vaccines. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a038448.	6.2	23

#	Article	IF	Citations
325	Attenuated activation of pulmonary immune cells in mRNA-1273â€“vaccinated hamsters after SARS-CoV-2 infection. Journal of Clinical Investigation, 2021, 131, .	8.2	23
326	Protecting the Family to Protect the Child: Vaccination Strategy Guided by RSV Transmission Dynamics. Journal of Infectious Diseases, 2014, 209, 1679-1681.	4.0	22
327	Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults. PLoS ONE, 2015, 10, e0123969.	2.5	22
328	Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine. Journal of General Virology, 2001, 82, 2107-2116.	2.9	22
329	Viruses, dendritic cells and the lung. Respiratory Research, 2001, 2, 245-9.	3.6	21
330	RhoA-Derived Peptide Dimers Share Mechanistic Properties with Other Polyanionic Inhibitors of Respiratory Syncytial Virus (RSV), Including Disruption of Viral Attachment and Dependence on RSV G. Journal of Virology, 2004, 78, 5015-5022.	3.4	21
331	Respiratory syncytial virus and other pneumoviruses: a review of the international symposiumâ€”RSV 2003. Virus Research, 2004, 106, 1-13.	2.2	21
332	Allergen-Induced Airway Hyperresponsiveness Mediated by Cyclooxygenase Inhibition Is Not Dependent on 5-Lipoxygenase or IL-5, but Is IL-13 Dependent. Journal of Immunology, 2005, 175, 8253-8259.	0.8	21
333	Evidence of Prior Exposure to Human Bocavirus as Determined by a Retrospective Serological Study of 404 Serum Samples from Adults in the United States. Vaccine Journal, 2009, 16, 597-604.	3.1	21
334	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine. Frontiers in Immunology, 2021, 12, 772864.	4.8	21
335	Structure-based design of stabilized recombinant influenza neuraminidase tetramers. Nature Communications, 2022, 13, 1825.	12.8	21
336	Pseudomonas aeruginosa Causing Osteomyelitis After Puncture Wounds of the Foot. Southern Medical Journal, 1984, 77, 1228-1230.	0.7	20
337	Pulmonary Dendritic Cell Subsets Shape the Respiratory Syncytial Virusâ€“Specific CD8+ T Cell Immunodominance Hierarchy in Neonates. Journal of Immunology, 2017, 198, 394-403.	0.8	20
338	HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. Journal of Virology, 2017, 91, .	3.4	20
339	Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level. Emerging Infectious Diseases, 2021, 27, 1-9.	4.3	20
340	Subtypes of type <scp>I IFN</scp> differentially enhance cytokine expression by suboptimally stimulated <scp>CD</scp>4⁺<scp>T</scp> cells. European Journal of Immunology, 2013, 43, 3197-3208.	2.9	19
341	Neutralizing antibody responses in Africa green monkeys naturally infected with simian immunodeficiency virus (SIVagm). Journal of Medical Primatology, 1999, 28, 97-104.	0.6	18
342	A Numerically Subdominant CD8 T Cell Response to Matrix Protein of Respiratory Syncytial Virus Controls Infection with Limited Immunopathology. PLoS Pathogens, 2016, 12, e1005486.	4.7	18

#	Article	IF	Citations
343	Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge. PLoS ONE, 2018, 13, e0205071.	2.5	18
344	Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. PLoS ONE, 2019, 14, e0222178.	2.5	18
345	Development and Standardization of a High-Throughput Multiplex Immunoassay for the Simultaneous Quantification of Specific Antibodies to Five Respiratory Syncytial Virus Proteins. MSphere, 2019, 4, .	2.9	18
346	Antigenic competition in CD4 ⁺ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. Science Translational Medicine, 2019, 11, .	12.4	18
347	Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. Journal of AIDS & Clinical Research, 2015, 06, .	0.5	17
348	DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial. PLoS ONE, 2015, 10, e0125914.	2.5	17
349	GM-CSF Production Allows the Identification of Immunoprevalent Antigens Recognized by Human CD4+ T Cells Following Smallpox Vaccination. PLoS ONE, 2011, 6, e24091.	2.5	16
350	Comparison of adjuvants to optimize influenza neutralizing antibody responses. Vaccine, 2019, 37, 6208-6220.	3.8	16
351	A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. Nature Medicine, 2022, 28, 373-382.	30.7	16
352	Antiviral Activity of RhoA-Derived Peptides against Respiratory Syncytial Virus Is Dependent on Formation of Peptide Dimers. Antimicrobial Agents and Chemotherapy, 2003, 47, 3470-3477.	3.2	15
353	Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F. Journal of Virology, 2017, 91, .	3.4	15
354	Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients. Frontiers in Immunology, 2021, 12, 615102.	4.8	15
355	Add-Fast Bacilli on Buffy Coat Smears in the Acquired Immunodeficiency Syndrome. Southern Medical Journal, 1984, 77, 246-248.	0.7	14
356	Cytokine release and innate immunity in respiratory viral infection. Seminars in Virology, 1996, 7, 255-264.	3.9	14
357	Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses. Journal of Antimicrobial Chemotherapy, 2004, 54, 299-302.	3.0	14
358	Clonotypeâ€specific avidity influences the dynamics and hierarchy of virusâ€specific regulatory and effector <scp>CD</scp>4⁺<scp>T</scp>â€cell responses. European Journal of Immunology, 2014, 44, 1058-1068.	2.9	14
359	Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012). PLoS ONE, 2016, 11, e0166393.	2.5	14
360	An R848-Conjugated Influenza Virus Vaccine Elicits Robust Immunoglobulin G to Hemagglutinin Stem in a Newborn Nonhuman Primate Model. Journal of Infectious Diseases, 2020, 224, 351-359.	4.0	14

#	Article	IF	Citations
361	Clostridial Infection of Renal Cell Carcinoma. Journal of Urology, 1986, 135, 354-355.	0.4	13
362	Phase I/II Preventive Vaccine Trials: Conference Summary. AIDS Research and Human Retroviruses, 1995, 11, 1279-1285.	1.1	13
363	Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates. PLoS ONE, 2020, 15, e0228572.	2.5	13
364	Influenza-infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem. JCI Insight, 2020, 5, .	5.0	13
365	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. EClinicalMedicine, 2022, 48, 101477.	7.1	13
366	Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. Contemporary Clinical Trials, 2015, 44, 112-118.	1.8	12
367	Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine. Journal of Infectious Diseases, 2019, 219, S107-S109.	4.0	12
368	A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcÎ³R-mediated protection against heterologous lethal influenza virus infection. International Immunology, 2019, 31, 81-90.	4.0	12
369	A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry. Journal of Virological Methods, 2019, 265, 77-83.	2.1	12
370	The Immune Space: A Concept and Template for Rationalizing Vaccine Development. AIDS Research and Human Retroviruses, 2014, 30, 1017-1022.	1.1	11
371	Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein ofÂMiddle East respiratory syndrome coronavirus. PLoS ONE, 2020, 15, e0232757.	2.5	11
372	VANDERBILT UNIVERSITY SCHOOL OF MEDICINE. Southern Medical Journal, 1989, 82, 1250-1258.	0.7	10
373	New Approaches to Vaccine Adjuvants: Inhibiting the Inhibitor. PLoS Medicine, 2006, 3, e57.	8.4	10
374	Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection. Journal of Allergy and Clinical Immunology, 2016, 138, 1477-1480.e5.	2.9	9
375	A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus. Virology, 2019, 534, 1-13.	2.4	9
376	Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model. The Lancet Healthy Longevity, 2022, 3, e405-e416.	4.6	9
377	Recent progress in immuneâ€based interventions to prevent HIVâ€1 transmission to children. Journal of the International AIDS Society, 2017, 20, e25038.	3.0	8
378	Features and Outcomes of Classic Heat Stroke. Annals of Internal Medicine, 1999, 130, 613.	3.9	8

#	Article	IF	Citations
379	Pericarditis Associated with Hemophilus influenzae Type B Pneumonia and Bacteremia in Two Adults. Chest, 1983, 84, 48-50.	0.8	7
380	Chikungunya in the Americas: Recommendations and Conclusions. Journal of Infectious Diseases, 2016, 214, S510-S513.	4.0	7
381	Level of maternal respiratory syncytial virus (RSV) F antibodies in hospitalized children and correlates of protection. International Journal of Infectious Diseases, 2021, 109, 56-62.	3.3	7
382	CD8+ TCR Transgenic Strains Expressing Public versus Private TCR Targeting the Respiratory Syncytial Virus KdM282â€“90 Epitope Demonstrate Similar Functional Profiles. PLoS ONE, 2014, 9, e99249.	2.5	7
383	Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. Science Translational Medicine, 2022, 14, .	12.4	7
384	Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. Clinical Pharmacology and Therapeutics, 2021, 109, 184-192.	4.7	6
385	Cancer Cellulitis. Southern Medical Journal, 1984, 77, 277-278.	0.7	5
386	Detection of Bacteremia and Fungemia: Microscopic Examination of Peripheral Blood Smears. Infection Control, 1984, 5, 448-452.	0.1	5
387	Extrapulmonary Thoracic Disease Caused by Blastomyces dermatitidis. Chest, 1994, 106, 1885-1887.	0.8	5
388	Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial. PLoS ONE, 2014, 9, e106240.	2.5	5
389	Limited Flavivirus Cross-Reactive Antibody Responses Elicited by a Zika Virus Deoxyribonucleic Acid Vaccine Candidate in Humans. Journal of Infectious Diseases, 2021, 224, 1550-1555.	4.0	5
390	Recurrent respiratory syncytial virus infection in a CD14 deficient patient. Journal of Infectious Diseases, 2022, , .	4.0	5
391	Counterfeit Calculi. Southern Medical Journal, 1984, 77, 304-307.	0.7	4
392	Pseudogout Presenting with Low Synovial Fluid Glucose: Identification of Crystals by Gram Stain. American Journal of the Medical Sciences, 1985, 289, 68-69.	1.1	4
393	Protective Role of TNF-Î± in Respiratory Syncytial Virus Infection In Vitro and In Vivo. American Journal of the Medical Sciences, 1996, 311, 201-204.	1.1	4
394	Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. Human Vaccines and Immunotherapeutics, 2012, 8, 630-638.	3.3	4
395	Phenotype and Hierarchy of Two Transgenic T Cell Lines Targeting the Respiratory Syncytial Virus KdM282-90 Epitope Is Transfer Dose-Dependent. PLoS ONE, 2016, 11, e0146781.	2.5	4
396	Hospitalization costs of respiratory syncytial virus infection. Pediatric Infectious Disease Journal, 2001, 20, 1100-1101.	2.0	4

#	Article	IF	Citations
397	Respiratory syncytial virus infection does not increase allergenâ€induced type 2 cytokine production, yet increases airway hyperresponsiveness in mice. Journal of Medical Virology, 2001, 63, 178-188.	5.0	3
398	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. SSRN Electronic Journal, 2020, , 3639618.	0.4	3
399	Interface between Animal Models and Clinical Phase I Trials Workshop: Conference Summary. AIDS Research and Human Retroviruses, 1995, 11, 1305-1306.	1.1	2
400	Potential for Directing Appropriate Responses to Vaccines by Cytokine Manipulation. BioDrugs, 1996, 5, 327-333.	0.7	2
401	VITAMIN A THERAPY FOR RESPIRATORY SYNCYTIAL VIRUS INFECTION. Pediatric Infectious Disease Journal, 1997, 16, 84-85.	2.0	2
402	Meeting the Challenge of Vaccine Design To Control HIV and Other Difficult Viruses. , 0, , 559-570.		2
403	Immunization Against Viral Diseases. , 0, , 351-370.		2
404	Functional reconstitution of the MERS CoV receptor binding motif. Molecular Immunology, 2022, 145, 3-16.	2.2	2
405	Clinical Trials of AIDS Vaccines in Seronegative Volunteers: Vectors and Combinations. AIDS Research and Human Retroviruses, 1992, 8, 1327-1328.	1.1	1
406	Clinical Trials of DNA and Recombinant Adenovector (rAd) Vaccines for HIV. Retrovirology, 2005, 2, S61.	2.0	1
407	CD8⁺ T-cell Mediated HIV Inhibition after Vaccination with a DNA/Recombinant Ad5 (rAd5) HIV Vaccine Is Similar to that Seen in Treated HIV Infection. AIDS Research and Human Retroviruses, 2014, 30, A84-A84.	1.1	1
408	Vaccines for Emerging Viral Diseases. , 2016, , 543-560.		1
409	Human Respiratory Syncytial Virus. , 2018, , .		1
410	Authors' Addendum. Journal of Medical Virology, 1991, 35, 307-307.	5.0	0
411	Reply to: Vitamin A for varicella. Journal of Pediatrics, 1994, 125, 1018.	1.8	0
412	Augmentation of allergic inflammation by cyclooxygenase inhibition is not dependent on IL-4. Journal of Allergy and Clinical Immunology, 2002, 109, S158-S158.	2.9	0
413	What does the report of the USMHRP Phase III study in Thailand mean for HIV and for vaccine developers?. Clinical and Experimental Immunology, 2009, 158, 257-259.	2.6	0
414	Tribute to David T. Karzon, MD and Robert M. Chanock, MD. Vaccine, 2011, 29, 3725-3727.	3.8	0

#	Article	IF	Citations
415	Future Opportunities for Passive Immunity Against Viral Diseases. Journal of Infectious Diseases, 2011, 204, 1648-1650.	4.0	0
416	VRC 311: Phase I Clinical Trial of a Virus-Like Particle Chikungunya Vaccine in Healthy Adults. Journal of Allergy and Clinical Immunology, 2013, 131, AB330.	2.9	0
417	Progress with PfSPZ Vaccine, a radiation attenuated Plasmodium falciparum sporozoite vaccine. Malaria Journal, 2014, 13, .	2.3	0
418	No Increase in Activated T Cells and Limited Increase in Adenovirus-specific T Cells in Colon and Rectal Mucosa Following HIV-1 DNA/rAd5 Immunization. AIDS Research and Human Retroviruses, 2014, 30, A48-A48.	1.1	0
419	Safety and immunogenicity of the heterologous prime-boost Ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BNÂ® FILO in healthy UK adults. Journal of Infection, 2015, 71, 688.	3.3	0
420	Zika Virus. , 2018, , 1266-1267.e1.		0
421	Vaccination Against Respiratory Syncytial Virus. , 2020, , 665-676.		0
422	Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses. Frontiers in Immunology, 2021, 12, 662909.	4.8	0